AcuCort

After consultation with the company's largest shareholders in terms of votes, as of September 30, 2022, the nomination committee consists of the following members:

• Sarah Fredriksson, appointed by AQILION AB
• Thomas Nestenius, appointed by Zoya Invest AB

The annual general meeting will be held on 4 May 2023 in Lund. The nomination committee's proposal will be presented in the notice to the annual general meeting and on the company's website.

For more information, please contact:

Ebba Fåhraeus, chairman of the board, telephone; 073 400 04 33, ebba@smileincubator.life

The information was submitted for publication, through the agency of the contact person above, on February 13, 2023.

About AcuCort AB (publ)
AcuCort AcuCort has developed and commercializes Zeqmelit®, a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need 2 supplemental oxygen therapy . Zeqmelit® is approved in Sweden, Denmark and Norway. All in all, it strengthens the company's assessment that the time until commercialization can be relatively short. AcuCort (short name: ACUC) is listed on the Spotlight Stock Market. Please visit www.acucort.se.